Hyphens Pharma International - SAC Capital 2023-10-20: Pursuing Growth Through Full Acquisition Of Ardence Pharma

• Hyphens Pharma's announced the acquisition of Ardence Pharma on 17 Oct 2023.

Broadening its regional exposure.

• Ardence Pharma, established in 2018, is a boutique pharmaceutical company specializing in aesthetic medicine. Its main products are PLINEST and NEWEST, injectable skin boosters originating from Italy carrying the European CE mark, and OXITHION, a supplement for skin brightening.
• - Read this at SGinvestors.io -

Global aesthetic medicine market expected to grow at 14.7% CAGR

• - Read this at SGinvestors.io -
• The acquisition would provide Hyphens Pharma access to new distribution lists and diversify product lines within a market poised for exponential growth, cementing its position as a major player.

Synergies and an experienced team make for an easy decision.

• Read more at SGinvestors.io.

Read also SAC's most recent report:
2025-03-10 Hyphens Pharma International - Strong Growth Momentum.

Previous report by SAC:
2024-08-22 Hyphens Pharma International - Commendable Growth Amid Economic Headwinds.

Price targets by other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividend Payout Dates & Corporate Actions,
Hyphens Pharma News